Envista Holdings (NVST) stock overview

Envista Holdings (NVST) has been drawing attention after recent share price moves, with the stock last closing at US$24.60 and showing mixed returns over the past year and past 3 months.

The recent 7 day share price return of 6.49% builds on a 30 day gain of 5.94%, yet the 3 year total shareholder return is down 26.50%. This highlights short term momentum compared with a weaker longer record.

If Envista’s recent rebound has you looking beyond a single stock, this is a good time to scan the market using the 40 healthcare AI stocks

With Envista’s shares rebounding recently, yet longer term returns still weaker, the key question is whether the current valuation and implied discount suggest room for upside, or whether the market is already pricing in future growth.

Most Popular Narrative: 14.3% Undervalued

Envista’s most followed narrative currently points to a fair value of $28.69 per share versus the last close of $24.60. This frames the recent rebound against a higher implied value.

The analysts have a consensus price target of $28.69 for Envista Holdings based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $35.0, and the most bearish reporting a price target of just $21.0.

Want to see what is sitting behind that valuation gap? The narrative leans on earnings growth, margin uplift and a richer future earnings multiple. You may be curious which assumptions really move the fair value line.

Result: Fair Value of $28.69 (UNDERVALUED)

However, the story can change quickly if China’s volume based procurement cuts deeper into brackets, wires and implants, or if tariffs and currency swings continue to pressure margins.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Angle: Earnings Multiple Sends A Different Signal

While the analyst fair value and our model point to NVST trading below intrinsic value, the earnings multiple tells a different story. The stock trades on a P/E of 59.1x, compared with about 24.5x for the US Medical Equipment industry and 45.1x for peers, and well above an estimated fair ratio of 29.5x.

This kind of gap suggests investors are already paying a premium for Envista’s earnings, so any stumble on execution or margins could matter more than the discount to fair value implies. Which signal do you treat as more important: the cash flow based fair value or the rich earnings multiple?

Next Steps

With mixed signals on valuation and sentiment, it helps to see the full picture for yourself and act before the story moves on. To see what investors are optimistic about, take a closer look at the 4 key rewards

Looking for more investment ideas?

If Envista has sharpened your focus, do not stop here. Broaden your watchlist with a few targeted stock ideas built from the Simply Wall St screener tools.

• Spot potential value opportunities early by scanning the market for 44 high quality undervalued stocks that combine price appeal with support from underlying fundamentals.
• Prioritize resilience by reviewing 71 resilient stocks with low risk scores that score well on financial strength and business stability.
• Get ahead of the crowd by checking the screener containing 20 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.